Board summary
Key figures
29,894
Registered population
60.4% aged 18–64
20.7%
Aged 65+
ICB 19.0% · England 17.9%
6.0%
Ethnic minority (non-White)
2.6% Asian · England 9.6%
29.3%
In IMD quintile 1
ICB 31.9% · England 21.0%
~10,702
Core20 residents (est.)
Resident basis; registered basis ~8,736 · see page 3
5,435
Hypertension register
+7.84% in 3 yrs · England +5.60%
314
SMI register
14.1% of Warrington (LAD)'s
698
COPD register
Reviews -5.42% in 3 yrs
Forecast to 2030
6,218
Hypertension patients, 2030
+783 on today
73.5%
QRISK ≥20% on statins, 2030
+5.29pp over 3 yrs
4.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Phone access varies sharply between practices.
Easy phone contact spans 34.6 pp from 32.2% at Fearnhead Cross Med.ctr. to 66.8% at Padgate Medical Centre, which could reflect demand pressures.
Diabetic statin therapy and BP control lag.
Statin treatment in diabetes aged 40+ without CVD is 65.9% (England 73.2%) and under-80 BP control is 65.0% (England 67.8%), suggesting review gaps.
Breast screening growth outpaced national average.
Breast screening coverage for ages 53 to 70 rose +12.2% from 2023 to 2024 (England +8.4%), reaching 71.3% against 69.9% across England.
Population, age and ethnicity
Registered patients aged 65+ reach 20.7%, yet recorded dementia prevalence is 0.5%
East Warrington PCN has 29,894 registered patients across three practices. Patients aged 65+ make up 20.7% (6,185 patients), above Warrington (LAD) (17.5 percent), NHS Cheshire and Merseyside ICB (19.0 percent) and England (17.9 percent). Area Census estimates of usual residents, rather than registered patients, record 94.0% White (Warrington (LAD) 93.5 percent, ICB 93.0 percent, England 81.1 percent) and 6.0% ethnic minorities. Across 14 catchment care homes (448 beds), recorded dementia prevalence is 0.5% (157 patients), below Warrington (LAD) (0.9 percent), the ICB (0.9 percent) and England (0.8 percent), leaving an unadjusted gap of +77 to +112 patients.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Warrington (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Warrington LA) | 1,737 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Warrington LA) | 905 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Warrington LA) | 12.1 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 29.3% PCN-wide and varies by 28.7 pp across practices
The PCN Core20 share is 29.3%, above Warrington (LAD) (16.9 percent) and England (21.0 percent), with an average IMD decile of 5.1. The range in Core20 prevalence across captured practices is 28.7 pp. Fearnhead Cross Med.ctr. has a Core20 share of 41.0%, representing an estimated 5,156 patients. Birchwood Medical Centre has a Core20 share of 26.2%. Padgate Medical Centre has a Core20 share of 12.3%. Across the PCN, 2 practices have a Core20 share above England. The estimated resident population in IMD deciles 1 and 2 is 10,702.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
314
SMI register
1.01% recorded prevalence
194
Learning disability register
0.63% recorded prevalence
14
Care homes, 448 beds
In the PCN catchment
9.4%
Provide unpaid care
Warrington (LAD), Census 2021
The PCN records 314 severe mental illness patients (1.0%, matching England's 1.0%) and 194 learning disability patients (0.6%, matching England's 0.6%), representing 14.1% and 15.8% of borough registers alongside 14 catchment care homes (448 beds). With recorded prevalence matching national benchmarks, sustaining annual physical health checks and structured reviews across these vulnerable groups is the primary operational priority.
Severe mental illness: physical health checks
SMI blood pressure coverage is 88.1% (England 83.4%). BMI recording fell 3.7 pp to 81.7% (England +5.1 pp), trailing at Padgate Medical Centre (65.5%) and Fearnhead Cross Med.ctr. (78.9%), while alcohol recording fell 3.9 pp (England +5.4 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,435
Hypertension register
+7.84%
Register growth, 3 yrs
Warrington (LAD) +6.41% · England +5.60%
+0.11pp
BP control, under 80
≤140/90 · +3.94pp aged 80+
+783
More patients by 2030
Forecast 6,218 (20.37%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.5% (5,435 patients), above Warrington (16.4%), the ICB (16.8%) and England (15.2%), with 3-year growth of +7.8% (England +5.6%). While 88.7% have a recent blood pressure reading, control under age 80 is 65.0%, below England (67.8%), Warrington (66.5%) and the ICB (66.4%), rising +0.2% over three years (England +3.2%). Control under 80 reaches 72.8% at Fearnhead Cross Med.ctr., but trails at Birchwood Medical Centre (59.9%) and Padgate Medical Centre (58.9%). Implied register denominators differ from list sizes, and figures include personalised care adjustments. Lagging blood pressure control under age 80 indicates an opportunity to prioritise clinical treatment escalation and structured recall at the two lowest-achieving practices.
Lipids and statins
Statin coverage in diabetes aged 40 and over without cardiovascular disease is 65.9%, trailing England (73.2%), Warrington (69.8%) and the ICB (72.4%). Primary prevention for QRISK ≥ 20% is 61.4% (England 63.6%). Fewer at-risk patients receive lipid-lowering therapy than national benchmarks imply, so proactive recall audits should prioritise diabetic primary prevention.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 51,897 | £1.50 | £1.71 | £1.86 | £77,846 |
| Cardiovascular (all), 2025 | 77,684 | £5.31 | £4.37 | £3.33 | £412,502 |
In 2026, the PCN prescribed 51,897 lipid-regulating items at £1.50 per item, below England (£1.86), Warrington (£1.59) and the ICB (£1.71). This spend is £18,683 less than at England's unit cost, across 51,897 items. Lower unit costs than England could allow the PCN to expand lipid therapy coverage without exceeding benchmark expenditure.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.14%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.59%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.2% (698 patients; England 1.9%), but annual reviews fell 5.4% over three years to 71.5% (England 76.4%, +2.8%), lowest at Birchwood Medical Centre (65.7%). Asthma prevalence is 7.8% (2,302 patients; England 6.6%), with annual review coverage at 66.6% (England 65.7%), leaving about 770 patients unreviewed. Asthma prescribing in ages 5-19 reaches 2,119 per 1,000 (England 1,488; Warrington (LAD) 1,534). This pattern may reflect routine review gaps, unverified locally; clinical audits would test this.
Cancer register and children's immunisation
The cancer register records 1,215 patients (3.9%; England 3.8%), growing +11.8% over three years (England +9.0%). For pre-school immunisation, MMR dose 1 reaches 98.2% at age 5 (England 91.7%), but dose 2 drops to 87.5% (England 82.8%), a 10.7 pp same-cohort drop that widens to 17.6 pp at Padgate Medical Centre (76.5%). Timely pre-school recall is essential to avoid under-immunisation before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of cancers with a known stage (7,482 of 13,490) in NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2, compared with 55.3% in England, remaining 19.5 pp below the 75.0% national ambition by 2028. Known-stage completeness was 72.8% (13,490 of 18,522 registrations; England 67.0%). Closing this gap would require about 2,640 additional early diagnoses across the ICB. These system metrics describe the ICB rather than PCN performance. Primary care contributes through screening and early detection; PCN cervical screening is 70.6% (Warrington (LAD) 71.6%), but Fearnhead Cross Med.ctr. records 68.8%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, North Cheshire and Mersey NHS Foundation Trust achieved 83.7% against the 85.0% 62-day cancer standard (1.3 pp below target), outperforming Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%), Manchester University NHS Foundation Trust (72.8%), NHS Cheshire and Merseyside Integrated Care Board (76.2%) and England (71.2%). The trust met the 28-day faster diagnosis standard at 80.2% (target 75.0%) and the 31-day standard at 98.2% (target 96.0%). In diagnostics, 6.3% waited 6+ weeks (England 23.1%), though colonoscopy was 16.0%. These reflect provider performance, not PCN activity.
| Pathways within standard (%) | North Cheshire and Mersey | Mersey and West Lancashire | Manchester | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.21 | 72.39 | 80.06 | 77.25 | 79.32 |
| 31-day treatment (96%) | 98.17 | 95.46 | 92.54 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 83.67 | 77.96 | 72.85 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | North Cheshire and Mersey | Mersey and West Lancashire | Manchester | England |
|---|---|---|---|---|
| MRI | 0.53 | 14.04 | 11.68 | 21.40 |
| CT | 2.32 | 13.08 | 14.66 | 9.92 |
| Echocardiography | 28.04 | 34.88 | 4.91 | 28.48 |
| Colonoscopy | 15.98 | 18.04 | 4.51 | 30.83 |
| Gastroscopy | 20.24 | 18.17 | 29.35 | 29.02 |
| All 15 DM01 tests | 6.34 | 21.17 | 8.98 | 23.14 |
| Community services activity | Warrington residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 38,550 | 541,280 |
| Referrals | 7,320 | 97,150 |
| Patients with a contact | 14,830 | 146,240 |
Community services (residents of Warrington), Jun 2026 (provisional). In June 2026, provisional community services data recorded 38,550 care contacts and 358,950 care activities for Warrington residents, alongside 1,332,205 activities across NHS Cheshire and Merseyside Integrated Care Board. Adults aged 65+ accounted for 56% of Warrington contacts (21,595 of 38,550). These experimental figures reflect submitting providers and resident activity rather than PCN-specific caseloads.
Practice variation and patient experience
Patient phone access varies by 34.6 pp across practices alongside uneven overall experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Padgate | 90 | 12.3 | 66.8% | 62.4% | 77.8% |
| Birchwood | 115 | 26.2 | 38.9% | 76.8% | 72.1% |
| Fearnhead Cross | 101 | 41.0 | 32.2% | 70.6% | 68.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
15 of 25 compared measures trail England on three-year change
Across 25 compared measures, 15 trail England on three-year change. The widest lags are in annual mental health checks: recording of alcohol consumption in psychosis fell 3.9 pp (Warrington (LAD) -0.9 pp, England +5.4 pp) and BMI recording fell 3.7 pp (Warrington (LAD) +0.2 pp, England +5.1 pp). COPD reviews dropped 5.4% (England +2.8%). Conversely, breast screening rose +12.2% (England +8.4%) and QRISK ≥ 20% lipid therapy rose +9.4% (England +6.2%). Declining review trends may reflect recall capacity constraints, unverified locally; recall audits would test this.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Alcohol record (psychosis)
BMI record (SMI)
COPD reviews
Learning disability register
Depression register
Breast screening (53-70)
QRISK statin treatment
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Warrington (LAD) | Asset | PCN | Warrington (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (448 beds) | n/a | Schools (catchment) | 69 | n/a |
| Children's centres | 6 | 12 | Places of worship | 26 | 89 |
| Libraries | 1 | 7 | Primary schools (LA maintained) | 13 | 28 |
| Primary academies | 14 | 31 | Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Respiratory annual review recall
Asthma review coverage is 66.6% of 2,302 patients (leaving 768, or about 770, unreviewed); COPD reviews fell 5.4% to 71.5% (England 76.4%), lowest at Birchwood Medical Centre (65.7%). For discussion: introduce single-template respiratory recall and flexible review slots across the 2,302 asthma and 698 COPD patients. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 2
Cardiovascular control and statin recall
BP control under 80 is 65.0% (England 67.8%), trailing at Padgate Medical Centre (58.9%) and Birchwood Medical Centre (59.9%); diabetic statin coverage is 65.9% (England 73.2%). For discussion: run pharmacist-led recall and titration reviews for uncontrolled hypertension and eligible diabetes or QRISK >=20% (61.4%) patients. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Dementia case-finding and care home review
Recorded dementia prevalence is 0.5% (157 patients) vs 0.8% in England and 0.9% in Warrington (LAD), an unadjusted gap of +77 to +112 patients despite 20.7% aged 65+. For discussion: audit clinical records for uncoded dementia diagnoses and conduct structured case-finding across the 14 catchment care homes (448 beds). Moderate effort to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Dementia register and coding review (p2) | Dementia: QOF prevalence | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
| Targeted Core20 proactive outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check audit (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension control recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall review (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony access and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Respiratory annual review recall (p12) | COPD register · Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Cardiovascular control and statin recall (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Dementia case-finding and care home review (p12) | Dementia register · Dementia: QOF prevalence · Aged 65+ | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
